MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
MetLife Inc. (MET) has a Rule 144 notice listing a proposed sale of 160 common shares for the account of MetLife Separate Account SPI, with an aggregate market value of $15,500.80. Barclays is named as broker, and the approximate sale date is October 6, 2026, on the NYSE. The notice also lists prior-period sales by separate MetLife accounts and the MetLife 401k Plan Trust-Large Cap Equity Index.
MetLife Inc. director Jeh C. Johnson was awarded 544 shares of common stock on October 1, 2026, at a reported price of $94.35 per share. His directly held position after the award was 10,101 shares.
MetLife Inc. director Robert Glenn Hubbard acquired 941 shares of common stock on October 1, 2026, at $94.35 per share under the company’s non-management director compensation arrangements. He elected to defer receipt of the shares under the MetLife Deferred Compensation Plan for Non-Management Directors; his direct holdings after the transaction were 109,132 shares.
MetLife Inc. director Christian Stephane Mumenthaler acquired 544 common shares on October 1, 2026; the reported price was $94.35 per share. The shares were part of non-management director retainer compensation, and Mumenthaler elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. His directly held common stock position after the transaction was 4,018 shares.
MetLife Inc. director Carla A. Harris acquired 544 shares of common stock on October 1, 2026, at a reported $94.35 per share, bringing her directly held position to 11,701 shares. The shares were part of non-management director retainer fees paid in stock; Harris elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.
MetLife Inc. director Mark A. Weinberger acquired 544 shares of common stock on October 1, 2026, as a grant under compensation arrangements that pay a portion of non-management director retainer fees in common stock. His directly held position after the award was 19,932 shares.
MetLife, Inc. director Diana McKenzie acquired 544 shares of common stock on October 1, 2026, as a portion of non-management director retainer fees paid in common stock. The reported price was $94.35 per share, and her direct holdings after the transaction were 25,929 shares. McKenzie elected to defer receipt of the shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
MetLife Inc. director Michelle Seitz acquired 544 common shares on October 1, 2026, in a director compensation award. MetLife’s non-management director compensation arrangements pay a portion of retainer fees in common stock. Seitz directly held 2,125 shares after the acquisition; the reported price per share was $0.0000.
MetLife, Inc. director Laura J. Hay acquired 544 shares of common stock on October 1, 2026, as a compensation award. The reported per-share amount was $94.35, and her reported direct holdings after the award were 6,901 shares. The shares represented a portion of non-management director retainer fees paid in common stock; Hay elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.
MetLife Inc. director Daniel S. Glaser acquired 544 shares of common stock as compensation on October 1, 2026; the reported per-share amount was $94.35. The shares were part of director retainer fees paid in stock, and Glaser elected to defer their receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. After the award, he reported 3,249 directly held shares and 198 shares held indirectly in a GRAT.